New Test Detects Nine Performance-Enhancing Muscle Growth Inhibitors in Athletes
Scientists develop comprehensive screening method for banned muscle-building drugs that block natural growth limiters.
Summary
Researchers developed a new laboratory test that can detect nine different banned performance-enhancing drugs called IASPs (inhibitors of activin receptor signaling pathways) in athlete blood and urine samples. These drugs work by blocking natural proteins that limit muscle growth and red blood cell production. The test uses advanced mass spectrometry and can detect these substances at very low levels (10-50 ng/mL) for up to 70 days after use. This breakthrough helps anti-doping agencies catch athletes using these emerging muscle-building drugs.
Detailed Summary
Anti-doping scientists have developed a comprehensive screening method to detect nine different performance-enhancing drugs that manipulate muscle growth pathways. These substances, called inhibitors of activin receptor signaling pathways (IASPs), work by blocking natural proteins like myostatin and activin A that normally limit muscle development and red blood cell production.
The research team created a single test that can simultaneously detect therapeutic antibodies (Garetosmab, Stamulumab, Landogrozumab, Domagrozumab, Apitegromab) and fusion proteins (Sotatercept, Elritercept, Luspatercept, Ramatercept) in both blood and urine samples. The method uses magnetic beads to capture the drugs, followed by protein digestion and high-resolution mass spectrometry analysis.
Validation studies showed the test can detect these substances at concentrations as low as 10-50 ng/mL. In real-world testing, Luspatercept remained detectable in both blood and urine for up to 70 days after the initial dose and 7 weeks after a second dose. Sotatercept was successfully identified in a blood sample collected 43 hours after injection.
These drugs are particularly concerning for sports integrity because they can significantly enhance athletic performance by promoting muscle growth and increasing oxygen-carrying capacity through enhanced red blood cell production. Several are already approved for treating muscle-wasting diseases and anemia, making them potentially accessible for misuse.
The new detection method addresses a critical gap in anti-doping testing, as these emerging substances were previously difficult to screen comprehensively. The test can be implemented in routine doping control laboratories as an initial screening procedure, helping maintain fair competition in sports.
Key Findings
- Successfully detected 9 different IASPs simultaneously with detection limits of 10-50 ng/mL in blood samples
- Luspatercept remained detectable in blood for up to 70 days after initial dose and 7 weeks after second dose
- Luspatercept was detectable in urine samples for up to 70 days post-administration
- Sotatercept was successfully identified in blood sample collected 43 hours after injection
- Method showed 100% specificity with no false positives in validation testing across 10 healthy volunteers
- Detection window extends significantly longer than typical performance-enhancing drugs
- Single test can screen for both therapeutic antibodies and fusion protein drug classes
Methodology
The study used liquid chromatography-high resolution tandem mass spectrometry (LC-HRMS/MS) with immunoaffinity purification using magnetic beads. Validation included 10 healthy volunteers (5 male, 5 female) for blank samples. Post-administration samples came from 4 volunteers who received Luspatercept (0.25 mg/kg) and 1 patient who received Sotatercept (0.5 mg/kg). The method employed tryptic digestion and multiple reaction monitoring for specific peptide detection.
Study Limitations
The study was limited by small sample sizes for post-administration testing (4 volunteers for Luspatercept, 1 for Sotatercept). The method requires specialized equipment and expertise not available in all laboratories. Authors noted that reference standards for some compounds may not be readily available for all testing facilities. The study focused on detection rather than quantification, limiting dose-response relationship understanding.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.